Citations

Clear

626 citation(s) found for "Mehta, SH".

Further Characterization of Hb Bronovo [α103(G10)His→Leu; HBA2: c.311A>T] and First Report of the Homozygous State
Mehta, Nikita , Johnston, J. Martin , Hein, Molly S., Kipp, Benjamin R. , Coon, Lea M., Savedra, Michelle E., Hoyer, James D., He, Rong , Rangan, Aruna , Oliveira, Jennifer L. , Herrick, Jennifer L. , Hein, Molly, Coon, Lea, Shi, Min

Mayo Clinic

Hemoglobin | June 18, 2020 | Volume: 44 | Issue: 3 | Pages: 174-178

10.1080/03630269.2020.1776322 | PMID 32552204 Get It

Trends, burden, and impact of arrhythmia on cardiac amyloid patients: A 16‐year nationwide study from 1999 to 2014
Isath, Ameesh , Correa, Ashish , Siroky, Gregory P. , Perimbeti, Stuthi, Mohammed, Selma F. , Chahal, C. Anwar A. , Padmanabhan, Deepak , Mehta, Davendra, Chahal, Choudhary Anwar A

Mayo Clinic

Journal of Arrhythmia | June 11, 2020 | Volume: 36 | Issue: 4 | Pages: 727-734

10.1002/joa3.12376 | PMID 32782646 Get It

AbstractBackgroundPatients with cardiac amyloidosis (CA) have increased mortality, which can be explained in part by an increased risk of arrhythmias. The burden of arrhythmias in CA, their predictors, and impact on in‐hospital outcomes remains unclear. The role of implantable cardioverter‐defibrillators (ICD) in this population is also uncertain.MethodsWe queried the National Inpatient Sample (NIS) using ICD‐9‐CM codes 277.39 and 425.7 to identify CA. Twelve common arrhythmias were extracted using appropriate, validated ICD‐9‐CM codes. ICD implantation was identified using procedure ICD‐9 codes 37.94 to 37.98, 00.51 and 00.54.ResultsThere were a total of 145,920 CA hospitalizations between 1999 and 2014 in the United States and 56,199 (38.5%) of them were associated with arrhythmias. The prevalence of arrhythmias remained relatively constant from 41.5% in 1999 to 40.2% in 2014. The most common arrhythmia was atrial fibrillation (25.4%). In‐patient mortality was significantly higher in CA patients with arrhythmias (10.4% vs 6.5%, P < .001). ICD implantation was performed in 1,381 (0.94%) patients with CA and analysis revealed an incremental trend in implantation over the study period (0.48% in 1999 to 0.65% in 2014). In‐hospital mortality was significantly lower in patients who underwent ICD implantation (3.7% vs 8%; P = .0078). CA patients with arrhythmias also had an increased cost of hospitalization and length of stay ($65,046 ± 1,079 vs $53,322 ± 687 and 8.3 ± 0.1 vs 7.4 ± 0.1 days, respectively; P < .0001).ConclusionCardiac arrhythmias are common in patients with CA and are associated with worse in‐hospital outcomes, increased length of stay, and cost of hospitalization.
Aminoglycosides in Immunocompromised Critically Ill Patients With Bacterial Pneumonia and Septic Shock: A Post-Hoc Analysis of a Prospective Multicenter Multinational Cohort
López, René , Salem, Omar Ben Hadj , Seguin, Amélie, Louw, Andry Van de , Klouche, Kada , Martín‐Loeches, Ignacio , Mehta, Sangeeta , Bruneel, Fabrice , Lisboa, Thiago , Viana, William, Pickkers, Peter, Russell, Lene , Rusínová, Kateřina , Kouatchet, Achille, Barbier, François , Russell, Lene , Martin-Loeches, Ignacio , Rello, Jordi , Taccone, Fabio Silvio , Bauer, Philippe R. , Metaxa, Victoria , Montini, Luca , Mokart, Djamel , Azoulay, Élie , Darmon, Michaël

Mayo Clinic

Shock | June 3, 2020 | Volume: 54 | Issue: 6 | Pages: 731-737

10.1097/shk.0000000000001553 | PMID 32496415 Get It

ABSTRACT Background: The routine use of empiric combination therapy with aminoglycosides during critical illness is associated with uncertain benefit and increased risk of acute kidney injury. This study aimed to assess the benefits of aminoglycosides in immunocompromised patients with suspected bacterial pneumonia and sepsis. Methods: Secondary analysis of a prospective multicenter study. Adult immunocompromised patients with suspected bacterial pneumonia and sepsis or septic shock were included. Primary outcome was hospital mortality. Secondary outcomes were needed for renal replacement therapy (RRT). Mortality was also assessed in neutropenic patients and in those with confirmed bacterial pneumonia. Results were further analyzed in a cohort matched on risk of receiving aminoglycosides combination. Results: Five hundred thirty-five patients were included in this analysis, of whom 187 (35%) received aminoglycosides in addition to another antibiotic effective against gram-negative bacteria. Overall hospital mortality was 59.6% (58.3% vs. 60.3% in patients receiving and not receiving combination therapy; P = 0.71). Lack of association between mortality and aminoglycosides was confirmed after adjustment for confounders and center effect (adjusted OR 1.14 [0.69–1.89]) and in a propensity matched cohort (adjusted OR = 0.89 [0.49–1.61]). No association was found between aminoglycosides and need for RRT (adjusted OR = 0.83 [0.49–1.39], P = 0.477), nor between aminoglycoside use and outcome in neutropenic patients or in patients with confirmed bacterial pneumonia (adjusted OR 0.66 [0.23–1.85] and 1.25 [0.61–2.57], respectively). Conclusion: Aminoglycoside combination therapy was not associated with hospital mortality or need for renal replacement therapy in immunocompromised patients with pulmonary sepsis.
Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States
Yu, Yang , Wadé, Niquelle Brown , Hwang, Amie E. , Nooka, Ajay K. , Fiala, Mark A. , Mohrbacher, Ann , Peters, Edward , Pawlish, Karen , Rand, Kristin A. , Conti, David V. , Auclair, Daniel , Mehta, Jayesh, Haiman, Christopher A. , Terebelo, Howard R. , Janakiraman, Nalini, Vij, Ravi , Bernal‐Mizrachi, Leon , Zonder, Jeffrey A. , Huff, Carol Ann , Orlowski, Robert Z. , Brown Wade, Niquelle , Van Den Berg, David J , Auclair, Daniel , Vij, Ravi , Zonder, Jeffrey A , Huff, Carol A , Cozen, Wendy , Ailawadhi, Sikander , Orlowski, Robert Z. , Fiala, Mark A , Nooka, Ajay K , Conti, David V , Yu, Yang, Bock, Cathryn Hufford , Berg, David Van Den , Stram, Daniel O. , Colditz, Graham A. , Singhal, Seema , Chiu, Brian C.‐H. , Lonial, Sagar , Cozen, Wendy , Ailawadhi, Sikander

Mayo Clinic

JCO Oncology Practice | May 29, 2020 | Volume: 16 | Issue: 10 | Pages: e1169-e1180

10.1200/jop.19.00639 | PMID 32469686 Get It

Purpose: Multiple myeloma (MM) treatment has changed tremendously, with significant improvement in patient out-comes. One group with a suboptimal benefit is patients with high-risk cytogenetics, as tested by conventional karyotyping or fluorescence in situ hybridization (FISH). Methodology for these tests has been published, but not necessarily standardized. Methods: We address variability in the testing and reporting methodology for MM cytogenetics in the United States using the ongoing African American Multiple Myeloma Study (AAMMS). We evaluated clinical and cytogenetic data from 1,221 patients (1,161 with conventional karyotyping and 976 with FISH) tested between 1998 and 2016 across 58 laboratories nationwide. Results: Interlab and intralab variability was noted for the number of cells analyzed for karyotyping, with a significantly higher number of cells analyzed in patients in whom cytogenetics were normal (P 5.0025). For FISH testing, CD138-positive cell enrichment was used in 29.7% of patients and no enrichment in 50% of patients, whereas the remainder had unknown status. A significantly smaller number of cells was analyzed for patients in which CD138 cell enrichment was used compared with those without such enrichment (median, 50 v 200; P, .0001). A median of 7 loci probes (range, 1-16) were used for FISH testing across all laboratories, with variability in the loci probed even within a given laboratory. Chromosome 13–related abnormalities were the most frequently tested abnormality (n5956; 97.9%), and t(14;16) was the least frequently tested abnormality (n 5 119; 12.2%). Conclusions: We report significant variability in cytogenetic testing across the United States for MM, potentially leading to variability in risk stratification, with possible clinical implications and personalized treatment approaches.
A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with high-grade glioma (Alliance A221101).
Porter, Alyx B. , Liu, Heshan , Kohli, Sadhna , Cerhan, Jane H. , Sloan, Jeff A. , Loprinzi, Charles L. , Jaeckle, Kurt A. , Brown, Paul D. , McMurray, Ryan P. , Le‐Rademacher, Jennifer , Villano, John L. , Kizilbash, Sani H. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 12007-12007

10.1200/jco.2020.38.15_suppl.12007 Get It

12007 Background: Up to 96% of patients with high grade glioma (HGG) report moderate to severe fatigue. Armodafinil, the R-enantiomer of modafinil, is a psychostimulant with low potential for abuse that has shown potential for improving severe fatigue in HGG patients. Methods: In this phase III double blinded placebo-controlled study, adults with HGG and moderate to severe fatigue, > 4 weeks after completing radiotherapy, were randomized to receive armodafinil daily (150 mg or 250 mg) or placebo for a total of 8 weeks. The primary outcome was efficacy in treating severe fatigue. Secondary outcomes included evaluation of tolerability, neurocognitive function, and quality of life. Patients were evaluated at baseline, 4 and 8 weeks. Results: A total of 328 patients were enrolled between 6/3/13-3/1/19. There were 103 (150 mg arm), 97 (250 mg arm) and 97 (placebo arm) evaluable patients with primary endpoint data available. The median age was 60 years (20-85) with a median Brief Fatigue Inventory (BFI) worst fatigue score of 8 (6-10). 60.3% were male, 80.5% received concomitant chemotherapy, and 39.7% were on corticosteroids. The global fatigue score at end of weeks 4 and 8 were lower than at baseline (p<0.0001) and in the 250 mg arm than placebo (p=0.0356) and was higher for corticosteroid users than non-users (p=0.0002). There was no statistically significant difference for clinically meaningful improvement in BFI usual fatigue score from baseline to end of week 8 between the three arms (p=0.9601). Patients reported an improvement in concentration at week 4 from baseline on the 150 mg arm(P=0.0311). There was no statistically significant difference on neurocognitive tests from baseline to end of week 4 (p>0.05) or week 8 (p>0.05) between arms. More patients reported insomnia on the 250 mg arm (p=0.0083). Conclusions: There is no meaningful benefit of the use of armodafinil to reduce moderate to severe fatigue in patients with HGG. In certain cases there may be benefit of armodafinil 150 mg to aid concentration without the risk of insomnia.Support: UG1CA189823;U10CA180868 (NRG). Clinical trial information: NCT01781468 .
Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424.
Pugh, Stephanie L. , Fisher, Barbara J., Lesser, Glenn J. , Macdonald, David R., McElroy, Joseph P., Rogers, Leland , Doyle, Thomas J. , Werner‐Wasik, Maria, Bahary, Jean-Paul , Yu, Michael , D’Souza, David , Sneed, Patricia Penny, Kwok, Young , Howard, Steven , Chakravarti, Arnab , Bell, Erica H. , Fleming, Jessica L. , Becker, Aline Paixão , Laack, Nadia N. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 2518-2518

10.1200/jco.2020.38.15_suppl.2518 Get It

2518 Background: This study sought to evaluate the prognostic significance of the three WHO-defined molecular glioma subgroups ( IDHwt, IDHmt/non-codel, and IDHmt/codel) in NRG Oncology/RTOG 0424, a phase II trial of high-risk low-grade gliomas treated with radiation (RT) and concurrent and adjuvant temozolomide (TMZ) after biopsy/surgical resection. Notably, this is the first clinical study to evaluate the prognostic value of the WHO subgroups in RT + TMZ-treated high-risk grade II (G2) gliomas using prospectively-collected long-term survival data. Methods: IDH1/2 mutation status was determined by next-generation sequencing. 1p/19q co-deletion status was determined by Oncoscan and/or 450K methylation data. Overall survival (OS) and progression-free survival (PFS) by marker status were determined by the Cox proportional hazard model and tested using the log-rank test in a post-hoc analysis. Patient pre-treatment characteristics were included as covariates in multivariate analyses. Results: Of all the eligible patients (N=129), 80 (62%) had sufficient quality DNA for both IDH and 1p/19q analyses. Of these 80, 54 (67.5%) were IDHmt, and 26 (32.5%) were IDHwt. Of the 54 IDHmt patients, 26 (32.5% of total, 48% of IDHmt) were IDHmt/codel, and 28 (35% of total, 52% of IDHmt) were IDHmt/non-codel. Both IDHmt subgroups were significantly correlated with longer PFS ( IDHmt/co-del = 8.1yrs (5.2-not reached (NR)); IDHmt/non-codel = 7.5yrs (3.9-11.8); IDHwt = 1.0yr (0.6-1.7), p<0.001) and OS ( IDHmt/co-del = 9.4yrs (8.2-NR); IDHmt/non-codel = 8.8yrs (5.9-NR); IDHwt = 2.3yrs (1.4-3.4), p<0.001) relative to the IDHwt subgroup. Upon univariate and multivariate analyses, both molecular IDHmt subgroup comparisons relative to IDHwt remained significant (p<0.001) even after incorporation of known clinical variables. Conclusions: These analyses suggest that G2 glioma patients harboring IDH1/2 mutations, regardless of co-deletion status, demonstrated longer survival with RT + TMZ relative to IDHwt tumors, although sample size is limited and analyses were post-hoc. These results also support the notion that outcomes for IDHwt high-risk G2 gliomas remain dismal (median = 2.3yrs, similar to G3 anaplastic astrocytoma); these patients should be separated from IDHmt patients in future G2 glioma trials, and warrant novel treatment strategies. Funding: U10CA180868, U10CA180822, U24CA196067, CURE, PA Dept. of Health, and Merck. Also, R01CA108633, R01CA169368, RC2CA148190, U10CA180850, BTFC, OSUCCC (all to AC). Clinical trial information: NCT00114140 .
The effect of using fecal testing after a negative sigmoidoscopy on the risk of death from colorectal cancer
Doubeni, Chyke A. , Corley, Douglas A. , Schottinger, Joanne E. , Lee, Jeffery K, Ghai, Nirupa R. , Levin, Theodore R. , Zhao, Wei , Saia, Chelsea , Wainwright, Jocelyn V. , Mehta, Shivan J. , Selby, Kevin , Doria‐Rose, V. Paul , Fletcher, Robert H., Saia, Chelsea A , Weiss, Noel S , Jensen, Christopher D. , Zauber, Ann Graham , Doubeni, Chyke A.

Mayo Clinic

Journal of Medical Screening | May 22, 2020 | Volume: 28 | Issue: 2 | Pages: 140-147

10.1177/0969141320921427 | PMID 32438892 Get It

Objective To examine whether receiving a fecal occult blood test after a negative sigmoidoscopy reduced mortality from colorectal cancer. Methods We used a nested case–control design with incidence-density matching in historical cohorts of 1,877,740 50–90-year-old persons during 2006–2012, in an integrated health-system setting. We selected 1758 average risk patients who died from colorectal cancer and 3503 matched colorectal cancer-free persons. Colorectal cancer-specific death was ascertained from cancer and mortality registries. Screening histories were determined from electronic and chart–audit clinical data in the 5- to 10-year period prior to the reference date. We evaluated receipt of subsequent fecal occult blood test within five years of the reference date among patients with negative sigmoidoscopy two to six years before the reference date. Results Of the 5261 patients, 831 patients (204 colorectal cancer deaths/627 controls) had either negative sigmoidoscopy only ( n = 592) or negative sigmoidoscopy with subsequent screening fecal occult blood test ( n = 239). Fifty-six (27.5%) of the 204 patients dying of colorectal cancer and 183 (29.2%) of the 627 colorectal cancer-free patients received fecal occult blood test following a negative sigmoidoscopy. Conditional regressions found no significant association between fecal occult blood test receipt and colorectal cancer death risk, overall (adjusted odds ratio = 0.93, confidence interval: 0.65–1.33), or for right (odds ratio = 1.02, confidence interval: 0.65–1.60) or left-colon/rectum (odds ratio = 0.77, confidence interval: 0.39–1.52) cancers. Similar results were obtained in sensitivity analyses with alternative exposure ascertainment windows or timing of fecal occult blood test. Conclusions Our results suggest that receipt of at least one fecal occult blood test during the several years after a negative sigmoidoscopy did not substantially reduce mortality from colorectal cancer.
Intrapleural Fibrinolytic Therapy versus Early Medical Thoracoscopy for Treatment of Pleural Infection. Randomized Controlled Clinical Trial
Kheir, Fayez , Thakore, S. , Mehta, Hiren J. , Jantz, Michael A., Parikh, Mihir , Chee, Alex, Kaphle, Upendra, Sisnega, Carlos, Fernández-Bussy, Sebastián , Majid, Adnan , Mehta, Hiren J

Mayo Clinic

Annals of the American Thoracic Society | May 18, 2020 | Volume: 17 | Issue: 8 | Pages: 958-964

10.1513/annalsats.202001-076oc | PMID 32421353 Get It

Abstract Rationale Pleural infection is frequently encountered in clinical practice and is associated with high morbidity and mortality. Limited evidence exists regarding the optimal treatment. Although both early medical thoracoscopy (MT) and tube thoracostomy with intrapleural instillation of tissue plasminogen activator and human recombinant deoxyribonuclease are acceptable treatments for patients with complicated pleural infection, there is a lack of comparative data for these modes of management. Objectives The aim of this study was to compare the safety and efficacy of early MT versus intrapleural fibrinolytic therapy (IPFT) in selected patients with multiloculated pleural infection and empyema. Methods This was a prospective multicenter, randomized controlled trial involving patients who underwent MT or IPFT for pleural infection. The primary outcome was the length of hospital stay after either intervention. Secondary outcomes included the total length of hospital stay, treatment failure, 30-day mortality, and adverse events. Results Thirty-two patients with pleural infection were included in the study. The median length of stay after an intervention was 4 days in the IPFT arm and 2 days in the MT arm (P = 0.026). The total length of hospital stay was 6 days in the IPFT arm and 3.5 days in MT arm (P = 0.12). There was no difference in treatment failure, mortality, or adverse events between the treatment groups, and no serious complications related to either intervention were recorded. Conclusions When used early in the course of a complicated parapneumonic effusion or empyema, MT is safe and might shorten hospital stays for selected patients as compared with IPFT therapy. A multicenter trial with a larger sample size is needed to confirm these findings. Clinical trial registered with ClinicalTrials.gov (NCT02973139).
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
Brazauskas, Ruta , Tecca, Heather R. , Bo‐Subait, Stephanie, Buchbinder, David , Battiwala, Minoo, Phelan, Rachel , Broglie, Larisa , Abraham, Allistair , Keating, Amy K. , Daly, Andrew , Wirk, Baldeep , Alter, Blanche P. , Üstün, Celalettin , Freytes, César O. , Beitinjaneh, Amer , Duncan, Christine , Copelan, Edward A. , Hildebrandt, Gerhard , Murthy, Hemant S. , Auletta, Jeffery J. , Page, Kristin , Vrooman, Lynda M. , Norkin, Maxim , Byrne, Michael , Kamani, Naynesh , Rezvani, Andrew R. , Farhadfar, Nosha , Mehta, Parinda A. , Hematti, Peiman , Shaw, Peter J. , Kamble, Rammurti T., Schears, Raquel M. , Hayashi, Robert J. , Mayo, Samantha , Rotz, Seth J. , Badawy, Sherif M. , Ganguly, Siddhartha , Pavletic, Steven Z. , Prestidge, Tim , Inamoto, Yoshihiro , Shaw, Bronwen E. , Satwani, Prakash , Battiwalla, Minoo , Schears, Raquel, Murthy, Hemant S , Badawy, Sherif M , Broglie, Larisa A , Battiwalla, Minoo , Auletta, Jeffery J , Hematti, Peiman , Kahn, Justine M , Flowers, Mary E.D. , Savani, Bipin N. , George, Biju , Lazarus, Hillard M. , Myers, Kasiani , Williams, Kirsten M. , Díaz, Miguel Ángel , Bhatt, Neel S. , Olsson, Richard F. , Gale, Robert Peter , Chhabra, Saurabh , Nishihori, Taiga , Agrawal, Vaibhav , Hogan, William J.

Mayo Clinic

Blood Advances | May 12, 2020 | Volume: 4 | Issue: 9 | Pages: 2084-2094

10.1182/bloodadvances.2019000839 | PMID 32396620 Get It

Abstract We examined the risk of subsequent neoplasms (SNs) and late mortality in children and adolescents undergoing allogeneic hematopoietic cell transplantation (HCT) for nonmalignant diseases (NMDs). We included 6028 patients (median age, 6 years; interquartile range, 1-11; range, &lt;1 to 20) from the Center for International Blood and Marrow Transplant Research (1995-2012) registry. Standardized mortality ratios (SMRs) in 2-year survivors and standardized incidence ratios (SIRs) were calculated to compare mortality and SN rates with expected rates in the general population. Median follow-up of survivors was 7.8 years. Diagnoses included severe aplastic anemia (SAA; 24%), Fanconi anemia (FA; 10%), other marrow failure (6%), hemoglobinopathy (15%), immunodeficiency (23%), and metabolic/leukodystrophy syndrome (22%). Ten-year survival was 93% (95% confidence interval [95% CI], 92% to 94%; SMR, 4.2; 95% CI, 3.7-4.8). Seventy-one patients developed SNs (1.2%). Incidence was highest in FA (5.5%), SAA (1.1%), and other marrow failure syndromes (1.7%); for other NMDs, incidence was &lt;1%. Hematologic (27%), oropharyngeal (25%), and skin cancers (13%) were most common. Leukemia risk was highest in the first 5 years posttransplantation; oropharyngeal, skin, liver, and thyroid tumors primarily occurred after 5 years. Despite a low number of SNs, patients had an 11-fold increased SN risk (SIR, 11; 95% CI, 8.9-13.9) compared with the general population. We report excellent long-term survival and low SN incidence in an international cohort of children undergoing HCT for NMDs. The risk of SN development was highest in patients with FA and marrow failure syndromes, highlighting the need for long-term posttransplantation surveillance in this population.
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020
Mehta–Shah, Neha , Ansell, Stephen M. , Barnes, Jeffrey A. , Clemens, Mark W. , Fisher, Kristopher , Goodman, Aaron M. , Guitart, Joan , Halwani, Ahmad , Haverkos, Bradley M. , Hoppe, Richard T. , Jacobsen, Eric D. , Jagadeesh, Deepa , Lunning, Matthew A. , Olsen, Elise A. , Pro, Barbara, Rajguru, Saurabh, Shaver, Aaron C., Shustov, Andrei R., Sokol, Lubomir , Torka, Pallawi , Torres‐Cabala, Carlos A. , William, Basem M. , Zain, Jasmine , Dwyer, Mary A., Sundar, Hema, William, Basem , Torres-Cabala, Carlos , Hoppe, Richard T , Horwitz, Sarah McCue , Ai, Weiyun Z. , Barta, Stefan K , Doǧan, Ahmet , Goyal, Gaurav , Mehta, Amitkumar , Shanbhag, Satish , Sokol, Lubomir , Wilcox, Ryan A. , Kim, Youn H

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 7, 2020 | Volume: 18 | Issue: 5 | Pages: 522-536

10.6004/jnccn.2020.0022 | PMID 32380458 Get It

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).